Abstracts tagged "Biologic drugs"

Abstract Number: 1913 • 2013 ACR/ARHP Annual Meeting
Expectations RA Patients Have For Their Treatment – A Comparison Of Clinical Results For Biologic and Disease-Modifying Anti-Rheumatic Drug Treated Patients Using Multiple Medical Cohorts
Tsukasa Matsubara^1,2, Hiroaki Matsuno², Tomomaro Izumihara², Yuichi Takahashi², Akira Sagawa², Motohiro Oribe², Eisuke Shono², Kensuke Kume², Masanori Adachi², Yuichi Nishioka², Nobumasa Miyake², Keisuke Hashimoto², Toshikaki Miyamoto², Shigeto Kiyokawa², Tomohiko Yoshida², Syoichi Kondo², Yoshiki Shiohira², Takanori Azuma², Yukio Sato², Masaaki Yoshida², Kenji Mannami², Akihiko Nakamura², Yasuhiko Hirabarashi², Keiko Funahashi³ and James E. Middleton⁴, ¹Department of Orthopedics, Matsubara Mayflower Hospital, Kato, Japan, ²Japanese Clinician's Biologic Research Group, Kobe, Japan, ³Department of Clinical Research, Matsubara Mayflower Hospital, Kato, Japan, ⁴Research Institute of Joint Diseases, Kobe, Japan
Background/Purpose: Treat to Target (T2T) primary principal - “The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist”. Japan…
Abstract Number: 1736 • 2013 ACR/ARHP Annual Meeting
A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Jan Brzezicki⁸, Eun Young Lee⁹, Francisco G. Medina-Rodriguez¹⁰, Pavel Shesternya¹¹, Sebastiao Radominski¹², Marina Stanislav¹³, Volodymyr Kovalenko¹⁴, Dong Hyuk Sheen¹⁵, Mie Jin Lim¹⁶, Jung-Yoon Choe¹⁷, Sung Young Lee¹⁸, Seung-Cheol Shim¹⁹ and Chang-Hee Suh²⁰, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Wojewodzki Szpital Zespolony Oddzial Reumatologiczny, Elblag, Poland, ⁹Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁰Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹¹Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹²CETI Centro de Estudos em Terapias Inovadoras Ltda, Curitiba, Brazil, ¹³Central Russian National Institute of Rheumatology, Russian Academy of Medical Science, Moscow, Russia, ¹⁴Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁵Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹⁶Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁷Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ¹⁸Clinical Planning and Medical Affairs Department, CELLTRION, Inc., Incheon, South Korea, ¹⁹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²⁰Department of Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose: CT-P10 was developed as a biosimilar candidate to innovator rituximab (RTX), an anti-CD20 monoclonal antibody. This trial is a phase I study to demonstrate…
Abstract Number: 1697 • 2013 ACR/ARHP Annual Meeting
Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?
Elizabeth V. Arkema¹, Jerker Jonsson², Eva Baecklund³, Maud Rutting⁴, Judith Bruchfeld⁵, Nils Feltelius⁴ and Johan Askling^1,6, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Swedish Institute for Communicable Disease Control, Solna, Sweden, ³Department of Medical Sciences, Rheumatology, Uppsala University Hospital, Uppsala, Sweden, ⁴Swedish Medical Products Agency, Uppsala, Sweden, ⁵Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].